Myelodysplastic Syndrome – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Myelodysplastic Syndrome – Pipeline Review, H1 2017’, provides an overview of the Myelodysplastic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome

The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects

The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Acceleron Pharma Inc

Actinium Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Agios Pharmaceuticals Inc

Aileron Therapeutics Inc

Altor BioScience Corp

Amgen Inc

Apogenix GmbH

Aprea AB

arGEN-X BV

Ariad Pharmaceuticals Inc

Arno Therapeutics Inc

Array BioPharma Inc

Astex Pharmaceuticals Inc

Atara Biotherapeutics Inc

Bayer AG

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Bio-Path Holdings Inc

BioLineRx Ltd

BioLite Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

Cantex Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellectis SA

Cellerant Therapeutics Inc

Celyad SA

Cornerstone Pharmaceuticals Inc

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Deciphera Pharmaceuticals LLC

Eisai Co Ltd

Eleos Inc

Eli Lilly and Company

EpiZyme Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Forma Therapeutics Inc

Fortress Biotech Inc

Fujifilm Corp

Gamida Cell Ltd

GlaxoSmithKline Plc

H3 Biomedicine Inc

IGF Oncology LLC

Immune System Key Ltd

ImmunoGen Inc

Incyte Corp

Io Therapeutics Inc

Jazz Pharmaceuticals Plc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Johnson & Johnson

JW Pharmaceutical Corp

Kainos Medicine Inc

KaloBios Pharmaceuticals Inc

Karyopharm Therapeutics Inc

Kiadis Pharma NV

Kyowa Hakko Kirin Co Ltd

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

medac GmbH

MediGene AG

MedImmune LLC

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Merus NV

Mesoblast Ltd

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Novartis AG

OncoImmune Inc

Onconova Therapeutics Inc

OncoTherapy Science Inc

Opsona Therapeutics Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Regen BioPharma Inc

Rich Pharmaceuticals Inc

Seattle Genetics Inc

Sorrento Therapeutics Inc

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sunesis Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Takara Bio Inc

Targazyme Inc

Teva Pharmaceutical Industries Ltd

Tolero Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

Trillium Therapeutics Inc

VasGene Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Myelodysplastic Syndrome - Overview 8

Myelodysplastic Syndrome - Therapeutics Development 9

Myelodysplastic Syndrome - Therapeutics Assessment 30

Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 48

Myelodysplastic Syndrome - Drug Profiles 100

Myelodysplastic Syndrome - Dormant Projects 827

Myelodysplastic Syndrome - Discontinued Products 832

Myelodysplastic Syndrome - Product Development Milestones 833

Appendix 846

List of Tables

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Myelodysplastic Syndrome – Pipeline by 4SC AG, H1 2017

Myelodysplastic Syndrome – Pipeline by AbbVie Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Acceleron Pharma Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Actinium Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Aeglea BioTherapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Agios Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Aileron Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Altor BioScience Corp, H1 2017

Myelodysplastic Syndrome – Pipeline by Amgen Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Apogenix GmbH, H1 2017

Myelodysplastic Syndrome – Pipeline by Aprea AB, H1 2017

Myelodysplastic Syndrome – Pipeline by arGEN-X BV, H1 2017

Myelodysplastic Syndrome – Pipeline by Ariad Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Arno Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Array BioPharma Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Atara Biotherapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Bayer AG, H1 2017

Myelodysplastic Syndrome – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by BerGenBio ASA, H1 2017

Myelodysplastic Syndrome – Pipeline by Bio-Path Holdings Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by BioLineRx Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by BioLite Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Myelodysplastic Syndrome – Pipeline by Boston Biomedical Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Bristol-Myers Squibb Company, H1 2017

Myelodysplastic Syndrome – Pipeline by Calithera Biosciences Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Cantex Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Celgene Corp, H1 2017

Myelodysplastic Syndrome – Pipeline by Celldex Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Cellectis SA, H1 2017

Myelodysplastic Syndrome – Pipeline by Cellerant Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Celyad SA, H1 2017

Myelodysplastic Syndrome – Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by CrystalGenomics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by CTI BioPharma Corp, H1 2017

Myelodysplastic Syndrome – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Myelodysplastic Syndrome – Pipeline by Eisai Co Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Eleos Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Eli Lilly and Company, H1 2017

Myelodysplastic Syndrome – Pipeline by EpiZyme Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Fate Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Forma Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Fortress Biotech Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Fujifilm Corp, H1 2017

Myelodysplastic Syndrome – Pipeline by Gamida Cell Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by GlaxoSmithKline Plc, H1 2017

Myelodysplastic Syndrome – Pipeline by H3 Biomedicine Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by IGF Oncology LLC, H1 2017

Myelodysplastic Syndrome – Pipeline by Immune System Key Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by ImmunoGen Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Incyte Corp, H1 2017

Myelodysplastic Syndrome – Pipeline by Io Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Jazz Pharmaceuticals Plc, H1 2017

Myelodysplastic Syndrome – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Johnson & Johnson, H1 2017

Myelodysplastic Syndrome – Pipeline by JW Pharmaceutical Corp, H1 2017

Myelodysplastic Syndrome – Pipeline by Kainos Medicine Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Kiadis Pharma NV, H1 2017

Myelodysplastic Syndrome – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Les Laboratoires Servier SAS, H1 2017

Myelodysplastic Syndrome – Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by MacroGenics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Mateon Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by medac GmbH, H1 2017

Myelodysplastic Syndrome – Pipeline by MediGene AG, H1 2017

Myelodysplastic Syndrome – Pipeline by MedImmune LLC, H1 2017

Myelodysplastic Syndrome – Pipeline by Medivir AB, H1 2017

Myelodysplastic Syndrome – Pipeline by MEI Pharma Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Merck & Co Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Merus NV, H1 2017

Myelodysplastic Syndrome – Pipeline by Mesoblast Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Mirati Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Novartis AG, H1 2017

Myelodysplastic Syndrome – Pipeline by OncoImmune Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Onconova Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by OncoTherapy Science Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Opsona Therapeutics Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Pfizer Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Pharma Mar SA, H1 2017

Myelodysplastic Syndrome – Pipeline by Plexxikon Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Regen BioPharma Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Rich Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Seattle Genetics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Sorrento Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Stemline Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Sunesis Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Takara Bio Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Targazyme Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Myelodysplastic Syndrome – Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Tragara Pharmaceuticals Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by Trillium Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Pipeline by VasGene Therapeutics Inc, H1 2017

Myelodysplastic Syndrome – Dormant Projects, H1 2017

Myelodysplastic Syndrome – Dormant Projects, H1 2017 (Contd..1), H1 2017

Myelodysplastic Syndrome – Dormant Projects, H1 2017 (Contd..2), H1 2017

Myelodysplastic Syndrome – Dormant Projects, H1 2017 (Contd..3), H1 2017

Myelodysplastic Syndrome – Dormant Projects, H1 2017 (Contd..4), H1 2017

Myelodysplastic Syndrome – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports